Clinical trials
Leukemia, B-cell clinical trials
Below are recruiting leukemia, b-cell clinical trials, each written for real people, not researchers. We’re tracking 273 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Miami Beach, FloridaAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07313982Recruiting
Leukemia study looking at LEF1 protein levels
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
Bologna, BOLOGNAAges 18 years+ - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT04836507RecruitingPhase 1/Phase 2
Study of a lab-made cell therapy for lymphoma and leukemia
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Bethesda, MarylandAges 18–110 - NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Duarte, CaliforniaAges 18 years+ - NCT00626496Recruiting
Family study for certain blood and immune disorders
This study looks at families where more than one close, blood-related person has a lymphoproliferative disorder (a group of conditions where the lymph system makes too many abnormal cells). It aims to better understand why these disorders run in families and how they may be inherited or related.
Rochester, MinnesotaAges 18–100 - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT02863692Recruiting
Registry study for chronic lymphocytic leukemia patients
This study is a registry that collects information about people with certain types of leukemia. It may help researchers understand the disease course and how patients are treated, including people who are newly diagnosed, currently treated, referred for transplant, or have relapsed.
Dresden, SaxonyAges 18 years+ - NCT02869529Recruiting
Chronic lymphatic leukemia patient database study
This study collects information from people diagnosed with chronic lymphatic leukemia. It may help doctors better understand the disease, track patient needs, and improve future care.
Marseille, Bouches-du RhôneAges 18–95 - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03375619Recruiting
Long-term follow-up after CAR-T treatment
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
Milwaukee, WisconsinAges 18–80 - NCT02473757Enrolling by invitation
Follow-up program for adults previously treated with CAR T
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Bethesda, MarylandAges 18 years+ - NCT07422337Recruiting
Vaccine protection after blinatumomab for childhood leukemia
This study checks how well vaccines you got as a baby still protect you after treatment with blinatumomab for B-cell leukemia or lymphoma. It helps doctors understand if you may need extra vaccines.
Little Rock, ArkansasAges 1–23 - NCT07429461RecruitingEarly Phase 1
SYNCAR-100 for relapsed B-ALL
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Hangzhou, ZhejiangAges 18–75 - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+ - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Stanford, CaliforniaAges 40 years+ - NCT05820841RecruitingPhase 3
Acalabrutinib plus R-miniCHOP for untreated lymphoma in older adults
This study tests whether adding acalabrutinib to a reduced-strength chemotherapy plan (R-miniCHOP) works better and is safer for older adults with newly diagnosed diffuse large B-cell lymphoma. It may help you get a more effective treatment while using a dosing approach meant for people who may not tolerate full-strength therapy.
Homburg, SaarlandAges 61 years+ - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07556757RecruitingPhase 1
CD-19 T-cell therapy for relapsed B-cell leukemia in teens and adults
This study tests a new engineered cell therapy (CD-19 t-haNK) designed to fight back B-cell acute lymphoblastic leukemia (a blood cancer) in patients whose cancer has returned or stopped responding to standard treatment. The therapy uses specially modified immune cells to target and destroy leukemia cells.
JohannesburgAges 12 years+ - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65
Hear when a new Leukemia, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, b-cell?
- Yes. Clin2 currently lists 273 recruiting leukemia, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.